References

1) Escherich T. Die Darmbacterien des Neugeborenen und Säuglings. Fortschr Med 1885;3:515–522, 547–554.

2) Escherich T. Die Darmbakterien des Säuglings und ihre Beziehung zur Physiologie der Verdauung. Stuttgart: Verlag Ferdinand Enke, 1886.

3) Sonnenborn U, Stobernack HP, Proppert Y. Die Entwicklung der aeroben Darmflora bei Neugeborenen. Fortschr Med 1990;108:420–424.

4) Schröder H. Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem E. coli-Stamm Nissle 1917. Der Kinderarzt 1992; 23(10): 1619–1625.

5) Hoogkamp-Korstanje JA et al. Composition and ecology of the human intestinal flora. ­Antonie Van Leeuwenhoek 1979; 45: 35–40.

6) Schulze J et al. Probiotika – Mikroökologie, Mikrobiologie, Qualität, Sicherheit und gesundheitliche Effekte. Hippokrates, Stuttgart, ISBN 978-3-8304-5356-7, 2008.

7) Bischoff SC. (Hrsg). Probiotika, Präbiotika und Synbiotika. Georg Thieme Verlag, Stuttgart, ISBN 978-3-13-144891-0, 2009.

8) Rasche C et al. Differential immunomodulating effects of inactivated ­probiotic bacteria on the allergic immune response. Acta Derm Venereol 2007; 87: 305–311.

9) Blum G et al. Properties of Escherichia coli strains of serotype O 6. Infection 1995; 23: 234–236.

10) Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic. Microbial Ecol Health Dis 2009; 21: 122–158.

11) Schiemann M et al. 125 Jahre E. coli – Bedeutung in Forschung und Medizin. Alfred-Nissle­-Gesellschaft (Hrsg.) Hagen, ISBN 3-9811198-4-3, 2010.

12) Troge A et al. More than a marine propeller – the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus. Int J Med Microbiol 2012; 302: 304–314.

13) Schlee M et al. Induction of human beta-defensin 2 by the probiotic Escherichia coli ­Nissle 1917 is mediated through flagellin.Infect Immun 2007; 75(5): 2399–2407.

14) Patzer S I et al. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003; 149: 2557–2570.

15) Oelschlaeger TA et al. Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic E. coli strain Nissle 1917. Gastroenterology 2001; 120: A326.

16) Boudeau J et al. Inhibitory effect of probiotic Escherichia coli strain ­Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive ­E. coli strains isolated from patients with Crohn‘s disease. Aliment Pharmacol Ther 2003; 18: 45–56.

17) Altenhoefer A et al. The probiotic Escherichia coli strain Nissle 1917 interferes with ­invasion of human intestinal epithelial cells by different enteroinvasive ­bacterial pathogens. FEMS ­Immunol Med Microbiol 2004; 40: 223–229.

18) Leatham MP et al. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect Immun 2009; 77: 2876–2886.

19) Reissbrodt R et al. Inhibition of growth of Shiga toxin-producing Escherichia coli by non­pathogenic Escherichia coli. FEMS Microbiol Lett 2009; 290: 62–69.

20) Kleta S et al. Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection. Infect Immun 2014; 82(5): 1801–1812.

21) Hacker J, Heesemann J. Molekulare Infektionsbiologie: Interaktionen zwischen Mikroorganismen und Zellen. Berlin: Spektrum Akademischer Verlag, 2000.

22) Cichon C et al. DNA-Microarray-based comparison of cellular responses in polarized T84 epithelial cells triggered by probiotics: E. coli Nissle 1917 (EcN) and Lactobacillus ­aci­dophilus PZ1041. Gastroenterology 2004; 126(4): A-578.

23) Schultz M et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and ­chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004; 11(2): 372–378.

24) Wehkamp J et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72(10): 5750–5758.

25) Lata J  et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol ­Hepatol 2007; 19: 1111–1113.

26) Zyrek AA et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCz redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804–816.

27) Ukena SN et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing ­mucosal integrity. PLOS ONE 2007; 12: e1308; 1–9.

28) Rund SA et al. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7. Int J Med Microbiol 2013; 303: 1–8.

29) Kruis W et al., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27(4): 467–474.
    30)     Bär F et al. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human ­colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21: 559-e17.

31) Sonnenborn U et al. Antimutagenic activity of the probiotic E. coli strain Nissle 1917. J Crohns Colitis 2009; 3: S136.

32) Otte JM et al. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009; 61(1): 103–113.

33) Hockertz S. Immunmodulierende Wirkung von abgetöteten apathogenen Escherichia coli Stamm Nissle 1917, auf das Makrophagensystem. Arzneim-Forsch/Drug Res 1991;41:1108–1112.

34) Hockertz S. Steigerung der körpereigenen Abwehr gegen Bakterien- und Pilz­infektionen bei Mäusen nach Vorbehandlung mit dem apathogenen Escherichia coli-Stamm Nissle 1917. Arzneim.-Forsch./Drug Res. 1997;47(I)(6): 793–796.

35) Lodinová-Žádníková R et al. Local and serum antibody response in ­fullterm and prema­ture infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (­Mutaflor). Pediatr Allergy Immunol 1992; 3: 43–48.

36) Lodinová-Žádníková R, Sonnenborn U. Effect of preventive administration of a nonpathogenic ­Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997; 71: 224–232.

37) Cukrowska B et al. Specific proliferative and antibody responses of ­premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain ­Nissle 1917. Scand J Immunol 2002; 55: 204–209.

38) Lodinová-Žádníková 1991, persönliche Mitteilung

39) Henker J et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007; 166(4): 311–318.

40) Henker J et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008; 27(6): 494–499.

41) Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiolo­gischen ­Esche­richia-coli-Bakterien. Med Klin 1994; 89: 587–593.

42) Bruckschen E, Horosiewicz H. Chronische Obstipation, Vergleich von mikrobiologischer Therapie und Lactulose. Münch Med Wochenschr 1994;16:241–245.

43) Kruis W et al. Double-blind comparison of an oral Escherichia coli ­preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853–858

44) Rembacken BJ et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635–639.

45) Kruis W, et al. Maintaining remission of ulcerative colitis with the pro­biotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617–1623.

46) Henker J et al. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative Colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008; 46: 874–875.

47) Matthes H et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010;10:13.

48) Travis SPL et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn‘s and Colitis 2008; 2(1): 24–62.

49) Malchow HA. Crohn‘s Disease and E. coli. J Clin Gastro­enterol 1997; 25: 653–658

50) Keller J et al. Reizdarm-Patienten mit Meteorismus als dominantem Symptom profitieren von einer Therapie mit E. coli Nissle 1917 – Ergebnisse einer Pilotstudie. Z Gastroenterol 2010; 48: 955.

51) Layer P. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011; 49: 237–293.

52) Krammer H et al. ­Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): ­Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 2006; 44: 651–656.

53) Plassmann D, Schulte-Witte H. Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey. Med Klin (Munich) 2007; 102(11): 888–892.

54) Goerg KJ, Schlörer E. Probiotic therapy of pseudomembranous colitis. Combination of intestinal lavage and oral administration of Escherichia coli. Dtsch Med Wochenschr 1998;123(43):1274–1278.

55) Goerg KJ et al. A new approach in pseudomembranous colitis: probiotic Escherichia coli Nissle 1917 after intestinal lavage. Eur J Gastroenterol Hepatol 2008; 20(2): 155–156.

56) Kuzela L et al. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001; 96: 3218–3219.

57) Tromm A et al. The probiotic E. coli strain Nissle 1917 for the treatment of collagenous ­colitis: First results of an open-labelled trial Z. Gastro­enterol 2004; 365–369.

58) Fricˇ P et al. The effect of non-pathogenic Escherichia coli in sympto­matic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003, 15; 313–315.

59) Henker J et al. Successful treatment of gut-caused halitosis with a suspension of living non-pathogenic Escherichia coli bacteria-a case report. ­Eur J Pediatr 2001; 160: 592–594.

60) Wurzel R. Prophylaxe der polymorphen Lichtdermatose. Akt Dermatol 1999; 25: 329–333.

61) Grozdanov L et al. A single nucleotide exchange in the wzy gene is ­responsible for the semirough O6 lipopolysaccharide phenotype and serum ­sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002; 184: 5912–5925.

62) Grozdanov L et al. Analysis of the Genome Structure of the Nonpathogenic Probiotic ­Escherichia coli Strain Nissle 1917 J Bacteriol. 2004; 186: 5432–5441.

63) Blum-Oehler G et al. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 2003; 154: 59–66.

64) Reister M et al. Complete genome sequence of the Gram-negative
probiotic Escherichia coli strain Nissle 1917. J Biotechnol 2014;187: 106–107.

References-List download

Mutaflor international package insert to download
Mutaflor Suspension international package insert to download